MBX Biosciences
Manufacturing · Indiana, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11711 N Meridian St Ste 300, Carmel, Ind...Phone Number
(317) 659-0200Website
www.mbxbio.comRevenue
-Stock Symbol
MBXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About MBX Biosciences
MBX Biosciences was founded in 2018, it is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX's leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. The company is supported by investment from leading life science investors that include Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates.Explore more
MBX Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MBX Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if MBX Biosciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if MBX Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at MBX Biosciences
MBX Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if MBX Biosciences is spiking on competitors!
Product Launch: Get notified when MBX Biosciences launches new products
Funding: Get notified immidiatlly once MBX Biosciences has new funding data
Earning: See what the market has to say on MBX Biosciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to MBX Biosciences
Compare insights from companies similar to MBX Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MBX Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MBX Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MBX Biosciences.
MBX Biosciences financials insights
Gather financial insights about MBX Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$34.6M
2022
Series B
$115M
2024
Series C
$63.5M
MBX Biosciences Tech Stack
A closer look at the technologies used by MBX Biosciences
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion
MBX Biosciences News & Media
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent HawrylukMBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide June 12, 2026 8:00 AM EDTCompany...MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society’s Annual MeetingChief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MBX Biosciences
Sign Up For FreeTo access detailed company insights
MBX Biosciences was founded in 2018, it is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX's leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class propr... Read More
